Xenon Pharmaceuticals (XENE) Operating Leases (2019 - 2026)

Xenon Pharmaceuticals (XENE) has 8 years of Operating Leases data on file, last reported at $5.9 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $5.9 million, down 18.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (down 18.69% YoY), and the FY2025 annual result was $6.4 million, down 16.14% from the prior year.
• Operating Leases retreated to $5.9 million in Q1 2026 per XENE's latest filing, from $6.4 million in the prior quarter.
• Over five years, Operating Leases peaked at $10.4 million in Q1 2023 and troughed at $5.9 million in Q1 2026.
• A 5-year average of $8.3 million and a median of $8.2 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2024: Operating Leases soared 185.91% in 2022, then fell 20.39% in 2024.
• A 5-year view of Operating Leases shows it stood at $9.9 million in 2022, then decreased by 3.45% to $9.6 million in 2023, then slipped by 20.39% to $7.6 million in 2024, then declined by 16.14% to $6.4 million in 2025, then dropped by 7.52% to $5.9 million in 2026.
• Business Quant data shows XENE's Operating Leases at $5.9 million in Q1 2026, $6.4 million in Q4 2025, and $6.8 million in Q3 2025.